PMID- 36740960
OWN - NLM
STAT- MEDLINE
DCOM- 20230413
LR  - 20230414
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 39
IP  - 4
DP  - 2023 Apr
TI  - Toward a better understanding of severe asthma phenotypes in Latin America: 
      results from the PREPARE study.
PG  - 627-638
LID - 10.1080/03007995.2023.2174328 [doi]
AB  - OBJECTIVE: Data on severe asthma phenotypes in Latin America are lacking. The 
      PREPARE study describes the prevalence of certain determinants of severe asthma 
      among patients in 5 Latin American countries with blood eosinophil counts (BEC) 
      >/=300 cells/mm(3) and serum immunoglobulin E (IgE) concentrations >100 IU/mL. 
      METHODS: In this cross-sectional study, information on demographics, disease 
      characteristics, and asthma treatments were extracted from the existing medical 
      records of patients aged >/=12 years attending centers specialized in severe asthma 
      management. Medical record data were transcribed onto electronic case report 
      forms. Blood eosinophil counts and IgE concentrations were assayed from specimens 
      obtained at study visit. Data were analyzed with descriptive statistics. RESULTS: 
      Data from 461 patients with severe asthma (mean age, 50.5 years) were analyzed. 
      Most patients were female (73%), had a body mass index of >/=25 kg/m(2) (77%), and 
      received full healthcare reimbursement (63%). In the previous 12 months, 52% of 
      patients experienced >/=1 severe exacerbation and 44% received oral corticosteroid 
      burst therapy. Blood eosinophil counts >/=300 cells/mm(3) and >/=150 cells/mm(3) were 
      reported in 44% and 76% of patients, respectively. In 58% of patients, serum IgE 
      concentrations exceeded 100 IU/mL. Uncontrolled asthma was documented in 50% 
      (n = 230) of patients. CONCLUSIONS: The PREPARE study provides useful insights 
      about the prevalence of eosinophilic and atopic phenotypes in patients with 
      severe asthma in Latin America, thereby paving the way for a more personalized 
      approach to managing severe asthma. Notwithstanding the treatment at specialized 
      medical centers, disease burden remained high in this study population.
FAU - Maspero, Jorge
AU  - Maspero J
AD  - Allergy and Respiratory Medicine, Fundacion CIDEA, Buenos Aires, Argentina.
FAU - Pavie, Juana
AU  - Pavie J
AD  - Medico Broncopulmonar, Centro Respiratorio Integral, Quillota, Chile.
FAU - Torres-Duque, Carlos A
AU  - Torres-Duque CA
AD  - Fundacion Neumologica Colombiana, CINEUMO, Research Department, Universidad de La 
      Sabana, Bogota, Colombia.
FAU - Montero-Arias, Felicia
AU  - Montero-Arias F
AD  - Servicio de Neumologia, Hospital Clinica Biblica Santa Ana, San Jose, Costa Rica.
FAU - Cerino-Javier, Ruth
AU  - Cerino-Javier R
AD  - Consultorio de Especialidad Alergologia Pediatrica, Hospital Angeles 
      Villahermosa, Tabasco, Mexico.
FAU - Rovira, Francisco
AU  - Rovira F
AD  - Respiratory & Immunology, AstraZeneca, Buenos Aires, Argentina.
FAU - Beekman, Maarten J H I
AU  - Beekman MJHI
AD  - Respiratory & Immunology, AstraZeneca, The Hague, the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230223
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - Female
MH  - Male
MH  - Latin America
MH  - Cross-Sectional Studies
MH  - *Asthma
MH  - Phenotype
MH  - Immunoglobulin E
OTO - NOTNLM
OT  - Clinicaltrials.gov Identifier NCT03931954
OT  - Severe asthma
OT  - asthma control
OT  - eosinophils
OT  - exacerbations
OT  - immunoglobulin E
OT  - treatment
EDAT- 2023/02/07 06:00
MHDA- 2023/04/13 06:42
CRDT- 2023/02/06 03:03
PHST- 2023/04/13 06:42 [medline]
PHST- 2023/02/07 06:00 [pubmed]
PHST- 2023/02/06 03:03 [entrez]
AID - 10.1080/03007995.2023.2174328 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2023 Apr;39(4):627-638. doi: 10.1080/03007995.2023.2174328. 
      Epub 2023 Feb 23.